BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update

The quest for BARD1's ELISA test takes another step forward.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The BARD1 Life Sciences Ltd (ASX: BD1) share price has walked through today's session in the green.

Before the open, BARD1 updated investors on a significant milestone in the development of its ELISA diagnostics test.

Let's investigate further.

A quick recap on BARD1 Life Sciences

BARD1 is a clinical diagnostics business with a focus on developing detection tests in a range of various cancers.

In addition, BARD1 also has a heavy interest in the research and development of non-invasive diagnostic tests for the early detection of cancer.

At the time of writing, BARD1 has a market capitalisation of $128 million.

What did BARD1 announce?

The company announced it had achieved proof of concept for its enzyme-linked immunosorbent assay (ELISA) based test for ovarian cancer.

BARD1's research partner at Griffith University showed how an initial ELISA test can detect a key biomarker found in tumour cells "from stages I–IV ovarian cancer".

Moreover, the ELISA test demonstrated it could detect the biomarker with "100% sensitivity and specificity" compared to the control group.

This is important because the test needs to "do what it says on the tin". That's to distinguish the biomarker in cases of ovarian cancer, not in "healthy controls" as BARD1 puts it.

As a result, it seems the outcome is a win for the ELISA regime, described as a "low-cost assay that can be performed in commercial laboratories worldwide", as per the release.

Moving forward, Griffith University and BARD1 will now "advance to the optimisation phase" for the ELISA test.

What did management say?

Referencing the data, BARD1 chief scientific officer, Dr Peter French said:

These data represent a key go decision to progress the optimisation and validation of our SubB2M ELISA-based tests that are expected to improve existing cancer biomarker tests for ovarian, breast, prostate and other cancers.

BARD1 Life Sciences share price snapshot

The BARD1 Life Sciences share price has climbed 114% into the green this year to date, extending the gain over the previous 12 months by 62%.

These results have outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

These ASX 200 shares could rise 25% to 80%

Analysts think big returns could be on offer from these shares.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Where to invest $5,000 into ASX 200 shares this month

The team at Bell Potter is bullish on these names. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

8 ASX 200 shares hitting multi-year highs today

These shares have defied the trend, hitting new price milestones amid a day in the red for the ASX 200.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Accent, Cettire, Ioneer, and Pro Medicus shares are dropping today

These shares are ending the week in the red. What's going on?

Read more »

A group of three miners in hard hats and high visibility vests confer at a rocky mining site.
Broker Notes

Up 66% in a year, just how much more upside does Macquarie tip for Perseus Mining shares?

Just how much higher might Perseus Mining shares soar? Here’s what Macquarie had to say about the ASX 200 gold…

Read more »